The high cost and risk of manufacturing failures in cell and gene therapy (CGT) pose significant challenges for timely production and delivery of safe, effective, and reliable allogeneic therapies to patients. Discovery’s AllCells® GMP Cryopreserved Peripheral Blood Mononuclear Cells (PBMCs) address these challenges by overcoming logistical and target cell isolation bottlenecks. Access to characterized, high-quality, GMP PBMCs minimizes manufacturing risks, enhances overall process efficiency, which results in cost-savings across development and commercialization.

With an agile team and advanced infrastructure, Discovery has supported many complex CGT programs. We specialize in developing tailored solutions that allow our clients to confidently translate and scale their CGT programs.